Metagenomi, Inc. (MGX)
NASDAQ: MGX · Real-Time Price · USD
1.780
-0.010 (-0.56%)
At close: Dec 5, 2025, 4:00 PM EST
1.780
0.00 (-0.02%)
After-hours: Dec 5, 2025, 7:07 PM EST
Metagenomi Revenue
Metagenomi had revenue of $8.66M in the quarter ending September 30, 2025, a decrease of -24.80%. This brings the company's revenue in the last twelve months to $30.91M, down -43.88% year-over-year. In the year 2024, Metagenomi had annual revenue of $52.30M with 16.84% growth.
Revenue (ttm)
$30.91M
Revenue Growth
-43.88%
P/S Ratio
2.15
Revenue / Employee
$153,035
Employees
202
Market Cap
66.83M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 52.30M | 7.54M | 16.84% |
| Dec 31, 2023 | 44.76M | 27.56M | 160.21% |
| Dec 31, 2022 | 17.20M | 16.96M | 6,978.19% |
| Dec 31, 2021 | 243.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionMGX News
- 4 days ago - Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference - GlobeNewsWire
- 18 days ago - Metagenomi to Present at Jefferies Global Healthcare Conference in London - GlobeNewsWire
- 23 days ago - Metagenomi Prioritizes Hemophilia A Program, Lays Off 25% Workforce - Benzinga
- 24 days ago - Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates - GlobeNewsWire
- 24 days ago - Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development - GlobeNewsWire
- 6 weeks ago - Metagenomi taps Amazon's custom chips to develop gene-editing tools - Reuters
- 4 months ago - Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results - GlobeNewsWire
- 4 months ago - Metagenomi Appoints Laurence Reid, PhD to its Board of Directors - GlobeNewsWire